Edition:
United States

Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

83.62USD
4:00pm EDT
Change (% chg)

$-0.80 (-0.95%)
Prev Close
$84.42
Open
$84.06
Day's High
$85.82
Day's Low
$82.96
Volume
525,515
Avg. Vol
496,738
52-wk High
$100.50
52-wk Low
$75.84

Chart for

About

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products... (more)

Overall

Beta: 1.68
Market Cap(Mil.): $14,864.02
Shares Outstanding(Mil.): 176.07
Dividend: --
Yield (%): --

Financials

  BMRN.OQ Industry Sector
P/E (TTM): -- 30.61 33.50
EPS (TTM): -0.43 -- --
ROI: -2.02 13.57 13.17
ROE: -2.68 15.25 14.98

BRIEF-European Medicines Agency Accepts Biomarin's Marketing Application For Pegvaliase

* EUROPEAN MEDICINES AGENCY (EMA) ACCEPTS BIOMARIN'S MARKETING APPLICATION FOR PEGVALIASE MAA FOR TREATMENT OF PHENYLKETONURIA (PKU)

Mar 28 2018

BRIEF-BioMarin Q4 GAAP Loss Per Share $0.30

* BIOMARIN ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Feb 22 2018

BRIEF-Biomarin Receives Anticipated Notification Of PDUFA Extension For Pegvaliase Biologics License Application

* BIOMARIN RECEIVES ANTICIPATED NOTIFICATION OF PDUFA EXTENSION FOR PEGVALIASE BIOLOGICS LICENSE APPLICATION (BLA) TO MAY 28, 2018

Dec 22 2017

BRIEF-Biomarin Doses First Patient In Late-Stage Trial Of Gene Therapy For Bleeding Disorder

* BIOMARIN DOSES FIRST PATIENT IN GLOBAL GENER8-1 PHASE 3 STUDY OF VALOCTOCOGENE ROXAPARVOVEC GENE THERAPY FOR SEVERE HEMOPHILIA A Source text for Eikon: Further company coverage:

Dec 19 2017

BRIEF-Biomarin Sells Second Priority Review Voucher For $125 Mln

* BIOMARIN SELLS SECOND PRIORITY REVIEW VOUCHER FOR $125 MILLION

Nov 27 2017

BRIEF-Biomarin reports Q3 loss $0.07/shr

* Q3 earnings per share view $-0.14 -- Thomson Reuters I/B/E/S

Oct 26 2017

BRIEF-FDA grants Breakthrough Therapy Designation for BioMarin's gene therapy for hemophilia A

* FDA grants Breakthrough Therapy Designation for BioMarin's valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy for hemophilia A

Oct 26 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $127.55 -0.17
Pfizer Inc. (PFE.N) $36.53 +0.04
Novartis AG (NOVN.S) CHF77.28 -1.52
Merck & Co., Inc. (MRK.N) $58.64 -0.28
Roche Holding Ltd. (ROG.S) CHF216.50 -0.05
Roche Holding Ltd. (RO.S) CHF220.20 -0.80
Abbott Laboratories (ABT.N) $59.88 +0.36
Bayer AG (BAYGn.DE) €99.60 -0.70
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €65.60 -0.21

Earnings vs. Estimates